Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SUSTAIRE vs KALEXATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
SUSTAIRE (budesonide/formoterol) is a fixed-dose combination of an inhaled corticosteroid (budesonide) and a long-acting beta2-adrenergic agonist (formoterol). Budesonide exerts anti-inflammatory effects by binding to glucocorticoid receptors, inhibiting inflammatory mediator release, and reducing airway hyperresponsiveness. Formoterol selectively activates beta2-adrenergic receptors in bronchial smooth muscle, causing bronchodilation via increased c AMP production.
KALEXATE is a monoclonal antibody that binds to both soluble and membrane-bound human interleukin-6 (IL-6) receptors, inhibiting IL-6-mediated signaling. IL-6 is a pro-inflammatory cytokine implicated in the pathogenesis of rheumatoid arthritis and other inflammatory conditions.
FDA-approved for maintenance treatment of asthma in patients aged 6 years and older,FDA-approved for maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults,Off-label: acute asthma exacerbations (as part of SMART therapy)
Treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs),Treatment of giant cell arteritis in adult patients
50 mg orally twice daily
10 mg orally once daily.
Terminal elimination half-life of 8-12 hours in healthy adults; prolonged in renal impairment.
12-15 hours; prolonged in renal impairment (up to 30 hours in severe cases)
Budesonide: extensively metabolized in the liver via CYP3A4 to inactive metabolites; formoterol: partially metabolized via glucuronidation and O-demethylation, with minor CYP involvement.
KALEXATE is a monoclonal antibody; it is catabolized into small peptides and amino acids via general protein degradation pathways. No specific metabolic enzymes or pathways are involved.
Primarily renal excretion (80-90% unchanged); minor biliary/fecal elimination (10-20%).
Primarily renal (75-80% as unchanged drug); biliary/fecal (15-20%)
Approximately 95% bound to albumin.
60-70% primarily to albumin
0.2-0.3 L/kg; indicates limited extravascular distribution primarily in plasma and interstitial fluid.
1.2-1.6 L/kg; indicates extensive extravascular distribution
Oral: 70-80% due to first-pass metabolism; intravenous: 100%.
Oral: 85-95%
GFR 30-59 m L/min: 50 mg once daily; GFR 15-29 m L/min: 25 mg once daily; GFR <15 m L/min: not recommended
GFR >= 60 m L/min: no adjustment; GFR < 60 m L/min: use not recommended.
Child-Pugh A: 50 mg twice daily; Child-Pugh B: 25 mg twice daily; Child-Pugh C: 12.5 mg once daily
Child-Pugh A: 5 mg once daily; Child-Pugh B: 2.5 mg once daily; Child-Pugh C: not recommended.
Weight-based: 0.5 mg/kg orally twice daily, max 25 mg per dose
Not approved for pediatric use.
Age >65 years: initiate at 25 mg twice daily; monitor renal function
No specific dose adjustment; monitor renal function.
Long-acting beta2-adrenergic agonists (LABAs) increase the risk of asthma-related death. SUSTAIRE is contraindicated for use as primary therapy for acute asthma exacerbations. For asthma, use only as add-on therapy for patients not adequately controlled on low-to-medium dose inhaled corticosteroids (ICS) or whose disease severity warrants initiation of ICS and LABA.
Risk of serious infections including tuberculosis, invasive fungal infections, and other opportunistic pathogens. Patients should be screened for latent tuberculosis prior to initiation. If serious infection develops, interrupt KALEXATE until infection is controlled.
LABA-associated asthma-related death; cardiovascular effects (tachycardia, hypertension); paradoxical bronchospasm; hypokalemia; hyperglycemia; increased susceptibility to infections; adrenal insufficiency with systemic steroid withdrawal; acute asthma exacerbation management.
Serious infections,Hepatotoxicity (elevated liver enzymes),Neutropenia,Thrombocytopenia,Lipid elevations,Gastrointestinal perforation (risk higher in patients with diverticulitis),Hypersensitivity reactions,Live vaccines should not be given concurrently
Primary treatment of status asthmaticus or acute asthma exacerbations; severe hypersensitivity to any ingredient.
Known hypersensitivity to KALEXATE or any of its excipients,Active infections including localized infections
No significant food interactions. Grapefruit or grapefruit juice may increase systemic exposure; avoid excessive consumption. No specific dietary restrictions required.
Avoid potassium-rich foods (bananas, oranges, potatoes, spinach, tomatoes, salt substitutes). Do not mix with fruit juices containing high potassium (e.g., orange, tomato). Maintain adequate fluid intake to prevent constipation.
Pregnancy Category C. First trimester: risk of major malformations unknown, but animal studies show fetal harm. Second/third trimester: potential for fetal respiratory depression, hypotonia, and withdrawal syndrome with chronic use. Avoid use unless benefit outweighs risk.
Kalexate (sodium polystyrene sulfonate) is not absorbed systemically and thus has no direct fetal exposure. However, electrolyte disturbances from maternal use (hypokalemia, hypernatremia) may indirectly affect fetal development. No specific teratogenic risk is documented; avoid severe maternal electrolyte imbalances.
Excreted in breast milk; M/P ratio approximately 0.24. Limited data suggests low infant dose (0.5-1% maternal weight-adjusted dose). Monitor infant for drowsiness and feeding difficulties. Consider risk-benefit.
Kalexate is not absorbed from the gastrointestinal tract, so systemic concentrations are negligible. M/P ratio is not applicable. Considered compatible with breastfeeding, but monitor infant for electrolyte imbalance if maternal use is prolonged.
No standard dose adjustment recommended. Increased plasma volume may reduce drug levels; monitor clinical response. Avoid near term due to risk of neonatal depression. Use lowest effective dose for shortest duration.
Standard dosing (15-60 g orally per day) may be used in pregnancy. No pharmacokinetic changes requiring dose adjustment as the drug is not absorbed. However, monitor electrolytes more frequently due to pregnancy-related volume expansion and altered renal function.
SUSTAIRE is an inhaled corticosteroid (ICS) used for maintenance treatment of asthma. It is not indicated for acute bronchospasm. Rinse mouth with water after each use to prevent oral candidiasis. Titrate to lowest effective dose to minimize systemic effects. Monitor for growth suppression in children and adrenal insufficiency during stress or prolonged use.
Kalexate (sodium polystyrene sulfonate) exchanges sodium for potassium in the gastrointestinal tract. Onset of action is 2-12 hours. Avoid in patients with hypokalemia, severe hypernatremia, or bowel obstruction. Monitor serum potassium and sodium levels regularly. Use with caution in patients with congestive heart failure or severe edema due to sodium load. Administer orally or as a retention enema; do not mix with fruit juices containing high potassium (e.g., orange juice).
Use SUSTAIRE regularly as prescribed, not for sudden breathing problems.,Rinse your mouth with water after each use to prevent thrush.,Do not stop taking SUSTAIRE without consulting your doctor, even if you feel better.,Keep track of your symptoms and peak flow if advised.,Seek medical help if your rescue inhaler is not working or you need more puffs than usual.
Take this medication exactly as prescribed to lower high potassium levels.,Do not mix with orange juice or other high-potassium beverages.,Drink plenty of water with each dose to prevent constipation.,Report any signs of bowel obstruction (severe abdominal pain, vomiting, no bowel movements) immediately.,Notify your doctor if you experience irregular heartbeat, muscle weakness, or numbness/tingling.,This medication contains sodium; inform your doctor if you have heart failure or high blood pressure.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SUSTAIRE vs KALEXATE, answered by our medical review team.
SUSTAIRE is a Methylxanthine Bronchodilator that works by SUSTAIRE (budesonide/formoterol) is a fixed-dose combination of an inhaled corticosteroid (budesonide) and a long-acting beta2-adrenergic agonist (formoterol). Budesonide exerts anti-inflammatory effects by binding to glucocorticoid receptors, inhibiting inflammatory mediator release, and reducing airway hyperresponsiveness. Formoterol selectively activates beta2-adrenergic receptors in bronchial smooth muscle, causing bronchodilation via increased c AMP production.. KALEXATE is a SSRI Antidepressant that works by KALEXATE is a monoclonal antibody that binds to both soluble and membrane-bound human interleukin-6 (IL-6) receptors, inhibiting IL-6-mediated signaling. IL-6 is a pro-inflammatory cytokine implicated in the pathogenesis of rheumatoid arthritis and other inflammatory conditions.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SUSTAIRE and KALEXATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SUSTAIRE is: 50 mg orally twice daily. The standard adult dose of KALEXATE is: 10 mg orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SUSTAIRE and KALEXATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SUSTAIRE is classified as Category C. Pregnancy Category C. First trimester: risk of major malformations unknown, but animal studies show fetal harm. Second/third trimester: potential for fetal respiratory depression, . KALEXATE is classified as Category C. Kalexate (sodium polystyrene sulfonate) is not absorbed systemically and thus has no direct fetal exposure. However, electrolyte disturbances from maternal use (hypokalemia, hypern. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.